Jared Whitlock

Reporter

Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

FERC Approves Sempra’s Oncor Bid

Sempra Energy’s $9.45 billion plan to obtain an ownership interest in Texas energy giant Oncor Electric took another step forward on Dec. 12.

Tease photo

Dart Neuroscience Laying Off 265 Employees, Shuttering Operations

The cessation will take effect Feb. 9.

Athena Names Holly Smithson as CEO

Smithson previously was the vice president of business strategy at the California Life Sciences Association.

Ionis Earns $45M Licensing Fee for Huntington’s Disease Drug

The Carlsbad drugmaker has licensed what’s being called a groundbreaking treatment following promising early trial results.

Halozyme Licensing Deal Could Be Worth Much More Than $40M

San Diego’s Halozyme Therapeutics will receive a $40 million upfront payment, and potentially much more, as part of a collaboration and licensing deal with Alexion Pharmaceuticals.

Metacrine Gets $22 Million in Funding Round, New Board Member

San Diego biotech Metacrine, which is working on drugs for liver and metabolic diseases, has closed a $22 million Series B financing round.

Executive Q&A Rakesh Patel, Neighborhood Healthcare

In 2002, Rakesh Patel started as a family physician at Neighborhood Healthcare, an organization he now leads.

Tease photo

Becoming Part of The (Health) Plan

Wellness Cos. Help Care and Coverage Providers Find Ways to Effectively Reach and Influence Diverse Customer Bases

Swaying rural teens in Arkansas to stay away from chewing tobacco, a habit ingrained in the local culture, is no easy task. Nor is crafting relatable messages for teens on the dangers of prescription painkiller abuse.

Tease photo

In Budget Move, Scripps Health to Cut Corporate Services By $30M

HEALTH: It Will Also Restructure Top Hospital Leadership

Scripps Health will cut corporate services by $30 million and replace the chief executive role at its hospitals with a new leadership model, according to media reports.

Tease photo

Metacrine Gets $22M in Funding Round, New Board Member

San Diego biotech Metacrine, which is working on drugs for liver and metabolic diseases, has closed a $22 million Series B financing round.

More stories >>